Cola JP, Nascimento do Prado T, Alves KBA, et al. Factors associated with non-completion of TB preventive treatment in Brazil. Int J Tuberc Lung Dis. 2023;27(3):215-220. doi:10.5588/ijtld.22.0571
Archives: Publications
Publications
Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa
McNabb KC, Bergman AJ, Patil A, et al. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa. BMC Public Health. 2024;24(1):578. Published 2024 Feb 23. doi:10.1186/s12889-024-17924-0
Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial
Semitala FC, Kadota JL, Musinguzi A, et al. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024;21(2):e1004356. Published 2024 Feb 20. doi:10.1371/journal.pmed.1004356
Active case-finding of tuberculosis compared with symptom-driven standard of care: a modelling analysis
Malhotra A, Ryckman TS, Johnson K, et al. Active case-finding of tuberculosis compared with symptom-driven standard of care: a modelling analysis. Int J Epidemiol. 2024;53(2):dyae019. doi:10.1093/ije/dyae019
Decline in prevalence of tuberculosis following an intensive case finding campaign and the COVID-19 pandemic in an urban Ugandan community
Kendall EA, Kitonsa PJ, Nalutaaya A, Robsky KO, Erisa KC, Mukiibi J, Cattamanchi A, Kato-Maeda M, Katamba A, Dowdy D. Decline in prevalence of tuberculosis following an intensive case finding campaign and the COVID-19 pandemic in an urban Ugandan community. Thorax. 2024 Jan 22:thorax-2023-220047. doi: 10.1136/thorax-2023-220047. Epub ahead of print. PMID: 38050134.
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review
Gerste AK, Majidulla A, Baidya A, Georgewill O, DeLuca AN, Pelzer PT, Gill MM, Jerene D, Buis JS, Kerkhoff AD, Limaye RJ. Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review. Expert Rev Vaccines. 2024 Jan-Dec;23(1):688-704. doi: 10.1080/14760584.2024.2375329. Epub 2024 Jul 10. PMID: 38967117.
Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa
Geiger K, Patil A, Bergman A, Budhathoki C, Heidari O, Lowensen K, Mthimkhulu N, McNabb KC, Mmed NN, Ngozo J, Reynolds N, Farley JE. Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa. Int J Tuberc Lung Dis. 2024 Jan 1;28(1):42-50. doi: 10.5588/ijtld.23.0242. PMID: 38178293.
The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates
Kasaie P, Pennington J, Gupta A, Dowdy DW, Kendall EA. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates. Clin Infect Dis. 2024;78(1):133-143. doi:10.1093/cid/ciad557
Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP
Rohilla A, Singh AK, Koleske B, Srikrishna G, Bishai WR. Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP. Microbiol Spectr. 2024;12(1):e0201223. doi:10.1128/spectrum.02012-23
Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis
Tucker EW, Ruiz-Bedoya CA, Mota F, Erice C, Kim J, de Jesus P, Jahdav R, Bahr M, Flavahan K, Chen X, Peloquin CA, Freundlich JS, Jain SK. Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis. Int J Antimicrob Agents. 2024 Jan;63(1):107048. doi: 10.1016/j.ijantimicag.2023.107048. Epub 2023 Dec 5. PMID: 38061419; PMCID: PMC10841818.